timothy sykes logo
TXG Stock Drops 13% As 10x Genomics Faces Sharp Selloff Thumbnail
G Google News

TXG Stock Drops 13% As 10x Genomics Faces Sharp Selloff

BRYCE TUOHEY•UPDATED OCT. 18, 2026, 11:06 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

10x Genomics Inc. stocks have been trading down by -4.05 percent amid concerns over weakening demand and slower revenue growth

Market Insights For TXG Traders

  • Shares slid 13.4% in a single session to $84.67, signaling heavy downside pressure and shaken confidence among short-term traders.
  • Recent weekly prices around the low $70s now sit well below that selloff close, showing continued weakness after the sharp drop.
  • Intraday action with a $71.91 open and rapid flush toward the high $60s reflects aggressive selling and elevated intraday volatility.
  • Strong gross margin and cash levels contrast with ongoing losses, creating a classic high-growth but high-risk trading profile.

Candlestick Chart

Weekly Update Oct 12 – Oct 16, 2026: On Sunday, October 18, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending down by -4.05%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

10x Genomics (TXG) remains a category leader in single-cell and spatial genomics with strong 70% gross margins and 3-year revenue CAGR near 3%, decelerating from 5-year 8–9% levels. However, profitability is weak: EBIT margin -12.8% and ROIC firmly negative, with retained losses of -$1.54B. Valuation is demanding at ~17x sales and ~13x book despite no P/E, but the balance sheet is solid with minimal leverage (debt/equity 0.1) and ample liquidity (current ratio 5.7, >$500M cash).

Technically, TXG is in a short-term corrective downtrend: the weekly sequence from 74.44 to 69.46 shows persistent lower highs and lower closes, confirming supply pressure after the recent sharp drop from the mid‑80s. Five‑minute candles exhibit heavy selling on down moves with higher relative volume, and an absence of strong intraday reversals. The key actionable level is $70: below it, traders should expect continued weakness toward $65; an aggressive long only makes sense above $74 with tight risk control.

The recent 13.4% single‑day selloff to the mid‑80s reflects rising concern over slowing growth and persistent losses, pressuring TXG versus broader Healthcare and Biotechnology & Life Sciences indices that currently favor profitable platforms. Near‑term sentiment is negative, but strategic demand from core academic and biopharma customers supports the long‑term story. I see near‑term resistance at $75–78, strong resistance near $85, and support at $65. Risk‑reward is unfavorable; maintain a cautious stance unless shares retest low‑60s.

More Breaking News

Quick Financial Overview

10x Genomics Inc. posted quarterly revenue of about $151.0M, with gross profit near $112.5M, which translates to a very strong 70% gross margin. That margin tells traders TXG can price its products well and control direct costs. The problem is further down the income statement, where heavy operating expenses drive an operating loss of roughly $23.0M and a net loss of about $17.9M for the quarter.

On a trailing basis, TXG shows about $642.8M in annual revenue, yet key profitability ratios remain firmly negative. Return on assets and return on equity are both below zero, confirming that 10x Genomics Inc. is still in a scale-up phase, not a steady-profit phase. Valuation is rich, with a price-to-sales ratio around 17.0 and very high price-to-cash-flow levels, which means traders are paying up for growth that is not yet hitting the bottom line.

The balance sheet, however, is a stabilizing factor. Cash and equivalents sit near $502.5M, with cash and short-term investments around $552.0M and total debt relatively modest near $66.8M. Liquidity looks strong, with a current ratio about 5.7 and quick ratio about 5.1, giving TXG room to fund losses and research. For short-term traders, that mix—negative earnings but strong cash—supports the idea of volatility trades rather than balance-sheet stress trades.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”